Epithalon

Typical Range

Forum-described protocols typically use 5–10 mg per dose subcutaneously. Khavinson-group studies in humans used a mix of intranasal and intramuscular administration at total doses in the low milligram range per course. Some longevity protocols cite 10 mg per dose daily for 10–20 days; others describe 5 mg per dose over longer intervals. Because no independent dose-finding trial exists, these numbers reflect convention rather than validated clinical recommendation.

Frequency

Typical user protocols involve daily injection across a short course (5 to 20 consecutive days), sometimes split into morning and evening doses. Chronic daily dosing is not described in the Khavinson clinical protocols and is not part of any longevity protocol in the published literature.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Cycle Length

The most commonly described schedule is a 10-day or 20-day course, often repeated every 6 months. The human cohort work usually cited for this schedule — a 266-person elderly cohort followed 6 to 8 years, and a Ukrainian coronary cohort given six courses over three years — did use repeated short courses spread across years, but it administered epithalamin rather than the Epithalon tetrapeptide, so it is a precedent for the shape of the schedule and not for this peptide's dose. Some longevity enthusiasts use shorter 5-day courses. Continuous daily administration is not standard and is not supported by the published protocols.

Protocol Notes

Route matters less for Epithalon than for some peptides, because the Khavinson group itself has used intranasal, intramuscular, and subcutaneous administration interchangeably in different studies. Forum protocols most commonly use subcutaneous injection into abdominal fat, citing ease of administration and assumed systemic exposure. Reconstitution is typically 10 mg lyophilized powder into 1–2 mL of bacteriostatic water, yielding a 5–10 mg/mL solution dosed on insulin syringes. The peptide is unstable in solution and should be refrigerated after reconstitution, with many sources recommending use within 1–2 weeks. The practical reality of Epithalon use outside Russia is that there is no clinician protocol to anchor to. Western clinicians do not prescribe it; Khavinson-group protocols are published in Russian-language and non-indexed journals and are difficult to verify independently. Anyone using Epithalon is relying on convention and forum consensus rather than anchored clinical guidance. Be honest with yourself about what that means for confidence in dose and duration.

Onset

There is no characterized onset profile in controlled clinical trials. Some users describe subjective sleep improvements (consistent with purported pineal/melatonin normalization) within the first few days of a course; others describe no noticeable acute effects at all, consistent with the protocol's stated orientation toward structural cellular changes rather than symptomatic effect. Telomerase activation, if it occurs as the Khavinson group reports, would not produce noticeable acute subjective effects.

Peak Effect

Khavinson-group protocols measure outcomes at the end of a treatment course (10–20 days) and in follow-up months later. Claimed effects on mortality in the elderly human cohorts are reported over multi-year follow-up, though those cohorts received epithalamin, the pineal extract, rather than the tetrapeptide. For individual users, any subjective peak effect is anecdotal and highly variable; the biological endpoints Epithalon is theorized to affect (telomere length, pineal signaling) are not measurable without specialized assays.

After Discontinuation

No documented withdrawal syndrome or rebound effect. If the peptide's claimed mechanism is correct — transient telomerase activation during the dosing course — then effects on telomere length would persist beyond dosing until counterbalanced by cell division. Subjective effects (if any) typically fade within days to weeks of cessation.

United States

Epithalon is not FDA-approved for any indication, is not recognized as a dietary supplement ingredient, and is not a legal cosmetic ingredient. Epitalon had been on FDA's 503A Category 2 list (bulk drug substances that may present significant safety risks); it came off that list on April 22, 2026, after its nominators withdrew the nominations, which does not authorize compounding. Its regulatory position also shifted in one specific and widely misreported way later in 2026. At the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting held on 23–24 July 2026, the committee considered seven nominated peptide bulk drug substances — BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and emideltide (DSIP), each in both free base and acetate forms — for possible inclusion on the Section 503A Bulk Drug Substances list. The committee voted to recommend six of the seven, epitalon among them; only emideltide was recommended against. FDA's own reviewers had argued against addition, citing short and underpowered studies insufficient to establish safety or effectiveness for the proposed indications. What that recommendation does and does not do matters more than the headline. PCAC is an advisory committee: its recommendations are non-binding and the FDA is not obligated to follow them. The vote did not authorize anyone to compound epitalon, and it did not change the current legal position. Before any substance is actually added to the 503A Bulks List, the FDA must complete formal notice-and-comment rulemaking. Even a completed rulemaking would not constitute FDA approval of epitalon as a drug — it would permit state-licensed 503A pharmacies to compound preparations from the bulk substance for an individually identified patient pursuant to a prescription, with no demonstration of efficacy required and no authority to market the substance or make therapeutic claims. As of this writing epitalon remains sold primarily through research-chemical suppliers not authorized for human use, in the same legal gray zone as before: not prohibited, not approved through any legitimate clinical pathway. On 28 October 2026 that ambiguity was partly resolved, though not in the way most coverage implied. HHS filed an enforcement discretion policy — Docket HHS-OASH-2026-0496, RIN 0910-ZD94, published in the Federal Register on 30 October as FR Doc. 2026-22192 and signed by Secretary Kennedy — stating that it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds a drug product using one of six named peptide bulk drug substances: BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. For epitalon the covered identity is the acetate salt, limited to subcutaneous and intramuscular injection and to intermittent courses rather than continuous use. The discretion is narrow and conditional. The active ingredient must come from an FDA-registered manufacturer operating under CGMP, with the manufacturing facility identified on the certificate of analysis — a repacker's or distributor's registration does not satisfy this — and must be supported by analytical testing covering identity including sequence, purity, potency, impurities, residual solvents, elemental impurities, microbial content and endotoxins. Each compounded product may contain only one covered active ingredient. Section 503A's patient-specific prescription requirement still applies, so this is not a licence for commercial-scale production, and the policy does not extend to 503B outsourcing facilities. Compounders must report product details to FDA and state authorities, report adverse events and quality problems through MedWatch, and label products with reporting instructions and the statement that this is a compounded drug product not for resale. What it is not is an approval. The notice states that FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list, that the policy does not establish any rights for any person and is not binding on HHS or the public, and that HHS may revisit it if a safety signal or product quality issue arises. Epitalon is still not on the 503A bulks list, nothing has been shown to be safe or effective, and FDA's own reviewers had recommended against all seven nominated peptides. The comment period runs roughly two weeks from publication, and the rulemaking that would make any of this durable is generally estimated at 12 to 24 months.

International

Not approved as a medicine in any Western regulatory jurisdiction. In Russia, Epithalon exists in a peculiar category — the Khavinson group's affiliated manufacturing operation has marketed peptide bioregulator products domestically, and some are registered as dietary supplements or investigational therapies, but Epithalon itself does not have the prescription-medicine approval status that Cerebrolysin or Selank have in Russia. It is not EMA, MHRA, TGA, or Health Canada approved.

Sports & Competition

Epithalon is not specifically listed on the WADA Prohibited List. Because it is not approved by any governmental health authority for human therapeutic use, it may be covered by WADA's S0 catch-all category prohibiting unapproved substances. Athletes subject to WADA code should treat it as prohibited until clarified with their anti-doping authority.